Galectin Q1 net loss narrows to $5.1M; belapectin data at EASL, FDA meeting ahead

GALECTIN THERAPEUTICS INC

2026-Q1 EPS reported -$0.08

Net loss of $5.1M ($0.08 per share) vs $9.6M ($0.15) in Q1 2025; R&D expense fell to $2.2M from $6.5M.
Cash $14.1M as of Mar 31, plus $10M credit line from chairman; company expects to fund ops through May 2027.
Belapectin 2 mg/kg showed statistically significant liver stiffness reductions (FibroScan) at Weeks 26, 52, 78 in NAVIGATE trial.
Oral/poster presentations at EASL Congress May 28-30; Type-C FDA meeting scheduled for Q2 2026.
Board appointed Dr. Henry Brem in Jan 2026; KOL event on MASH cirrhosis held in March 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.